Iovance Biotherapeutics (IOVA) Insider Trading & Ownership $2.23 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.22 -0.01 (-0.45%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Iovance Biotherapeutics (NASDAQ:IOVA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$9.74KNumber OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$503K Get IOVA Insider Trade Alerts Want to know when executives and insiders are buying or selling Iovance Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IOVA Insider Buying and Selling by Quarter Iovance Biotherapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/23/2025Raj K PuriInsiderBuy5,600$1.74$9,744.00 11/12/2024Ryan D MaynardDirectorSell50,000$10.06$503,000.00 (Data available from 1/1/2013 forward) IOVA Insider Trading Activity - Frequently Asked Questions Who is on Iovance Biotherapeutics' Insider Roster? The list of insiders at Iovance Biotherapeutics includes Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak, Raj K Puri, Ryan D Maynard, and Wayne P Rothbaum. Learn more on insiders at IOVA. What percentage of Iovance Biotherapeutics stock is owned by insiders? 10.30% of Iovance Biotherapeutics stock is owned by insiders. Learn more on IOVA's insider holdings. Which Iovance Biotherapeutics insiders have been buying company stock? The following insiders have purchased IOVA shares in the last 24 months: Merrill A Mcpeak ($2,343,100.00), Raj K Puri ($9,744.00), and Wayne P Rothbaum ($26,500,000.00). How much insider buying is happening at Iovance Biotherapeutics? Insiders have purchased a total of 5,265,600 IOVA shares in the last 24 months for a total of $28,852,844.00 bought. Which Iovance Biotherapeutics insiders have been selling company stock? The following insider sold IOVA shares in the last 24 months: Ryan D Maynard ($503,000.00). How much insider selling is happening at Iovance Biotherapeutics? Insiders have sold a total of 50,000 Iovance Biotherapeutics shares in the last 24 months for a total of $503,000.00 sold. Iovance Biotherapeutics Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Compensation: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Compensation: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Compensation: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Compensation: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information Technology More Insider Trading Tools from MarketBeat Related Companies Protagonist Therapeutics Insider Buying Apellis Pharmaceuticals Insider Buying MoonLake Immunotherapeutics Insider Buying Mirum Pharmaceuticals Insider Buying Kymera Therapeutics Insider Buying Scholar Rock Insider Buying Bausch Health Cos Insider Buying Xenon Pharmaceuticals Insider Buying AMNEAL PHARMACEUTICALS Insider Buying NewAmsterdam Pharma Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Costco Faces Downgrades, Death Cross, Insider SellingReynolds Consumer Products Stock Price: Insiders Signal a BottomBuy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say Buy This page (NASDAQ:IOVA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access